From the shareholder alert,notice the last sentenc
Post# of 72440
I find it encouraging and intriguing.
"Remember, the coronavirus research is at no cost to our company, so anything that can be gleaned about the antiviral,
anti-inflammatory and other mechanistic properties of Brilacidin will be extremely valuable to us going forward in
combination with the litany of clinical data collected on Brilacidin as an antibacterial and anti-inflammatory.
To that point, President Trump passing comments about wanting to streamline onerous components of the FDA process
has sparked new discussions about the known robust antibacterial properties of Brilacidin."
Kelt